152 related articles for article (PubMed ID: 20646447)
1. [Clinical significance of Her-2/neu status in patients with uterine papillary serous carcinoma].
Ren YL; Wang HY; Zhou XY; Shan BE; Yang WT; Shen L; Shi DR
Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):367-71. PubMed ID: 20646447
[TBL] [Abstract][Full Text] [Related]
2. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
3. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
Slomovitz BM; Broaddus RR; Burke TW; Sneige N; Soliman PT; Wu W; Sun CC; Munsell MF; Gershenson DM; Lu KH
J Clin Oncol; 2004 Aug; 22(15):3126-32. PubMed ID: 15284264
[TBL] [Abstract][Full Text] [Related]
4. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
[TBL] [Abstract][Full Text] [Related]
5. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization.
Odicino FE; Bignotti E; Rossi E; Pasinetti B; Tassi RA; Donzelli C; Falchetti M; Fontana P; Grigolato PG; Pecorelli S
Int J Gynecol Cancer; 2008; 18(1):14-21. PubMed ID: 17451461
[TBL] [Abstract][Full Text] [Related]
6. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
Afify AM; Werness BA; Mark HF
Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of HER-2/neu in uterine serous papillary cancer.
Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
[TBL] [Abstract][Full Text] [Related]
8. Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression.
Nordström B; Strang P; Lindgren A; Bergström R; Tribukait B
Anticancer Res; 1996; 16(2):899-904. PubMed ID: 8687148
[TBL] [Abstract][Full Text] [Related]
9. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
[TBL] [Abstract][Full Text] [Related]
10. Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.
Mahdi H; Xiu J; Reddy SK; DeBernardo R
J Surg Oncol; 2015 Aug; 112(2):188-94. PubMed ID: 26250968
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma.
Díaz-Montes TP; Ji H; Smith Sehdev AE; Zahurak ML; Kurman RJ; Armstrong DK; Bristow RE
Gynecol Oncol; 2006 Jan; 100(1):139-44. PubMed ID: 16182348
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of 14-3-3σ is predictive of poor prognosis for patients with human uterine papillary serous carcinoma.
Suzuki F; Nagase S; Suzuki K; Oba E; Hiroki E; Matsuda Y; Akahira J; Nishigori H; Sugiyama T; Otsuki T; Yoshinaga K; Takano T; Niikura H; Ito K; Sasano H; Yaegashi N
Tohoku J Exp Med; 2013 Nov; 231(3):193-9. PubMed ID: 24201220
[TBL] [Abstract][Full Text] [Related]
13. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
Mentrikoski MJ; Stoler MH
Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
[TBL] [Abstract][Full Text] [Related]
14. HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed?
Santin AD
Gynecol Oncol; 2003 Mar; 88(3):263-5. PubMed ID: 12648572
[No Abstract] [Full Text] [Related]
15. Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.
Batman S; Bohn J; Weisenberger MW; Hersh A; Bruegl A; Caughey A; Winter W
Gynecol Oncol; 2021 Jan; 160(1):214-218. PubMed ID: 33393480
[TBL] [Abstract][Full Text] [Related]
16. [Uterine papillary serous carcinoma--a different kind of tumor].
Steinman N; Avni A
Harefuah; 1999 May; 136(10):810-2. PubMed ID: 10955120
[No Abstract] [Full Text] [Related]
17. Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation.
Singh P; Smith CL; Cheetham G; Dodd TJ; Davy ML
Int J Gynecol Cancer; 2008; 18(6):1344-51. PubMed ID: 18248390
[TBL] [Abstract][Full Text] [Related]
18. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder.
Coogan CL; Estrada CR; Kapur S; Bloom KJ
Urology; 2004 Apr; 63(4):786-90. PubMed ID: 15072912
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG
Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
